Literature DB >> 10817714

Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents.

M Marschall1, M Freitag, S Weiler, G Sorg, T Stamminger.   

Abstract

A recombinant human cytomegalovirus (AD169-GFP) expressing green fluorescent protein was generated by homologous recombination. Infection of human fibroblast cultures with AD169-GFP virus produced stable and readily detectable amounts of GFP signals which were quantitated by automated fluorometry. Hereby, high levels of sensitivity and reproducibility could be achieved, compared to those with the conventional plaque reduction assay. Antiviral activities were determined for four reference compounds as well as a set of putative novel cytomegalovirus inhibitors. The results obtained were exactly in line with the known characteristics of reference compounds and furthermore revealed distinct antiviral activities of novel in vitro inhibitors. The fluorometric data could be confirmed by GFP-based flow cytometry and fluorescence microscopy. In addition, laboratory virus variants derived from the recombinant AD169-GFP virus provided further possibilities for study of the characteristics of drug resistance. The GFP-based antiviral assay appeared to be very reliable for measuring virus-inhibitory effects in concentration- and time-dependent fashions and might also be adaptable for high-throughput screenings of cytomegalovirus-specific antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817714      PMCID: PMC89918          DOI: 10.1128/AAC.44.6.1588-1597.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

Authors:  S Chou; A Erice; M C Jordan; G M Vercellotti; K R Michels; C L Talarico; S C Stanat; K K Biron
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

2.  A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells.

Authors:  S Zolotukhin; M Potter; W W Hauswirth; J Guy; N Muzyczka
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

3.  Replacement mutagenesis of the human cytomegalovirus genome: US10 and US11 gene products are nonessential.

Authors:  T R Jones; V P Muzithras; Y Gluzman
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

4.  Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.

Authors:  R F Azad; V Brown-Driver; R W Buckheit; K P Anderson
Journal:  Antiviral Res       Date:  1995-10       Impact factor: 5.970

5.  The lytic transition of Epstein-Barr virus is imitated by recombinant B-cells.

Authors:  M Marschall; P Alliger; F Schwarzmann; C Bogedain; M Brand; B Reichelt; G Glaser; H Wolf
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

6.  A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate.

Authors:  F Baldanti; E Silini; A Sarasini; C L Talarico; S C Stanat; K K Biron; M Furione; F Bono; G Palù; G Gerna
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

Review 7.  Current management of cytomegalovirus disease in patients with AIDS.

Authors:  M A Jacobson
Journal:  AIDS Res Hum Retroviruses       Date:  1994-08       Impact factor: 2.205

8.  The dominant phosphoprotein pp65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture.

Authors:  S Schmolke; H F Kern; P Drescher; G Jahn; B Plachter
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Construction of a herpes simplex virus/varicella-zoster virus (HSV/VZV) thymidine kinase recombinant with the pathogenic potential of HSV and a drug sensitivity profile resembling that of VZV.

Authors:  F Bevilacqua; N Davis-Poynter; J Worrallo; D Gower; P Collins; G Darby
Journal:  J Gen Virol       Date:  1995-08       Impact factor: 3.891

10.  Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.

Authors:  M A Polis; K M Spooner; B F Baird; J F Manischewitz; H S Jaffe; P E Fisher; J Falloon; R T Davey; J A Kovacs; R E Walker
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

View more
  49 in total

1.  Human parainfluenza virus type 3 (HPIV-3): construction and rescue of an infectious, recombinant virus expressing the enhanced green fluorescent protein (EGFP).

Authors:  Jason P Roth; Joseph K-K Li; Dale L Barnard
Journal:  Curr Protoc Microbiol       Date:  2010-05

2.  Human cytomegalovirus glycoprotein B variants affect viral entry, cell fusion, and genome stability.

Authors:  Jiajia Tang; Giada Frascaroli; Robert J Lebbink; Eleonore Ostermann; Wolfram Brune
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-19       Impact factor: 11.205

3.  Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections.

Authors:  Nina Tavalai; Peer Papior; Sabine Rechter; Martina Leis; Thomas Stamminger
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations.

Authors:  Corina Hutterer; Jan Eickhoff; Jens Milbradt; Klaus Korn; Isabel Zeitträger; Hanife Bahsi; Sabrina Wagner; Gunther Zischinsky; Alexander Wolf; Carsten Degenhart; Anke Unger; Matthias Baumann; Bert Klebl; Manfred Marschall
Journal:  Antimicrob Agents Chemother       Date:  2015-01-26       Impact factor: 5.191

5.  Cyclin-dependent Kinases Phosphorylate the Cytomegalovirus RNA Export Protein pUL69 and Modulate Its Nuclear Localization and Activity.

Authors:  Sabine Rechter; Gillian M Scott; Jan Eickhoff; Katrin Zielke; Sabrina Auerochs; Regina Müller; Thomas Stamminger; William D Rawlinson; Manfred Marschall
Journal:  J Biol Chem       Date:  2009-01-29       Impact factor: 5.157

6.  Human embryonic lung fibroblasts treated with artesunate exhibit reduced rates of proliferation and human cytomegalovirus infection in vitro.

Authors:  Ai-Hong Zeng; Yang-Ying Ou; Ming-Ming Guo; Xuan Dai; De-Zhi Zhou; Rui Chen
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

7.  Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.

Authors:  Rike Webel; Morgan Hakki; Mark N Prichard; William D Rawlinson; Manfred Marschall; Sunwen Chou
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

8.  Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay.

Authors:  Yoshiko Fukui; Keiko Shindoh; Yumiko Yamamoto; Shin Koyano; Isao Kosugi; Toyofumi Yamaguchi; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

9.  A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays.

Authors:  Jason P Roth; Joseph K-K Li; Donald F Smee; John D Morrey; Dale L Barnard
Journal:  Antiviral Res       Date:  2009-02-02       Impact factor: 5.970

10.  Human cytomegaloviruses expressing yellow fluorescent fusion proteins--characterization and use in antiviral screening.

Authors:  Sarah Straschewski; Martin Warmer; Giada Frascaroli; Heinrich Hohenberg; Thomas Mertens; Michael Winkler
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.